Doubts of Hengrui Pharmaceutical: the cost of sales ratio is at the average level of the industry _ 东方 东方网

Original title: Suspicion of Hengrui Medicine: Cost of sales ratio is at the mid-level of the industry

Recently, a criminal sentence issued by a Zhejiang court revealed the bribery case of Lei Mou, a former director of a hospital’s anesthesia department, and nearly ten medical or medical devices.companyInvolve. The content of the verdict was sent and interpreted by multiple media and continued to ferment online.

On the afternoon of May 12,Hengrui MedicineActive launchAdAnswer questions from the media.the companySaid the incident was an individual employee of the subsidiarybehavior, A serious violation of the companyadministrationsystem. Currently, relevant personnel have left the company.responsibilityThe leader has been transferredSend. In the future, the company will learn lessons and strengthen itsCompliance managementTo prevent such things from happening.

Announced that 2019Hengrui MedicineSalesThe expense ratio is 36.61%. According to the data, the company’s sales expense ratio is found in the Shanghai and Shenzhen stock markets.Pharmaceutical manufacturingAmong the more than 230 companies in the industry (including API companies), it is ranked 85th and is in the middle of the industry. These sales expenses mainly include companiesproductAcademic promotion, construction of an innovative platform for specialization in medicine, etc.marketcost,Travel expensesas much asEquityexcitementRates, etc.

The ad took the initiative to list sales expenses as the media focused on where they were spent. Of sales expenses, market expenses such as academic promotion and the construction of specialized platforms for innovative medicines accounted for 88.29%, while academic activities represented more than half of this market, mainly used to organizemeetingAnd promotional activities, support for medical exchanges and patient education, as well as innovative medicines independently developed by the company, which carry out a series of academic activities at different stages, doctors use drugsKnowledgeTraining, management of adverse reactions, etc.

The announcement indicated that as more senior academic and medical talents were introduced to the sales force in recent years, sales staff travel standards have also increased year after year.TravelIncreased frequency, travel and related expensestolerance, Expenses on meals and other expenses increased.

Why did the sales expenses during the prevention and control of the epidemic questioned by the media not decrease significantly?Hengrui MedicineHe said that in the first quarter of 2020, the company’s sales activities requiring on-site communication were affected by the epidemic, but sales expenses included sales personnel.salary,Five insurance and one gold.Office expenses, academic research and other relatively fixed expenses, and with the increase in sales staff and improved treatment, the corresponding expenses have increased.

As a leading innovative pharmaceutical company in China, Hengrui Medicine has formed a batch of listed, developed and clinical batches. This is normal for a large amount of academic promotion, and your sales expense ratio is in the middle of the industry ranking. Typical.

Industry experts said that with the deepening of reforms in the national fields of pharmaceutical, medical and medical insurance, especially standardization and broad promotion of centralized national purchases of medicines, it is an inevitable trend that national sales expenses of medications will decrease dramatically in the future. Pharmaceutical companies’ rules of survival, and cost savings, will ultimately benefit the drug.ConsumptionBy.

(Editor in charge: DF524)